PIRCHE AG, headquartered in Berlin Germany, is the exclusive provider of the technology named PIRCHE® and related matching services. The company is offering these services through its web-based portal to its customers.
PIRCHE® is seen as a ground-breaking technology. The company is pursuing the final validation with internationally recognized clinical and scientific partners.
Up to now, the allocation of a suitable transplant for a patient (bone marrow as well as solid organs) has been primarily based on the so-called HLA Types (Human Leucocyte Antigenes). This group of genes is responsible for the expression of proteins on the surface of those human cells, which are responsible for the immune reactions between the patient and the transplant. Existing epitope matching algorithms are focused on direct recognition of the major histocompatibility complex.
PIRCHE® takes this approach further, going directly into the analysis of the amino acids, which are the building blocks of proteins. Sophisticated algorithms working on the company's proprietary CordMatch® IT-system are the background of this quantum leap in applied transplantation science. In contrast to direct recognition epitope matching models, PIRCHE® calculates indirectly recognizable HLA epitopes unveiling the previously overlooked indirect immune response.
Patented, proprietary technology and IT-systems enabling transplant physicians and medical coordinators at the registries to find optimally matched transplants for patients who couldn’t find the right match in the past. Extensive retrospective validation studies in thousands of patients have shown that an appropriate PIRCHE® score between patient and transplant leads to a significantly improved survival and quality of life.
PIRCHE AG serves the transplant community by creating truly innovative software solutions for challenges in creating the optimal match between organ and patient. We believe that our collaborative approach empowers us to facilitate decision making for donor registries, transplant physicians and laboratory specialists on a global scale.
Currently, PIRCHE AG offers two solutions in the field of transplantation medicine:
The PIRCHE® portal allows the selection of permissible single mismatch donors in cases where a perfect match is not available. This might open up significant new avenues in the field of hematopoietic and solid organ transplantation and improve outcomes for patients in need.
CordMatch® is a state-of-the-art matching tool for cord blood, developed by clinicians and engineers to respond to the needs for the actual stem cell search process. CordMatch® can be extended to other stem cell sources like unrelated allogeneic stem cells from voluntary donors, making it a universal matching tool for clinicians and stem cell donor registries.
Together with leading institutions PIRCHE AG strives to further develop PIRCHE® to become a standard in hematopoietic stem cell and solid organ transplantation.
Click here to register for the PIRCHE portal for your daily clinical or registry practice.
If you are interested in a scientific collaboration with the PIRCHE AG team, please contact us.
Press Releases and Newsletters
- Paper on PIRCHE-II in kidney transplantation featured on Transplant Campus
- Dutch Society for Immunology awards Eric Spierings for PIRCHE
- Tech Newsletter #2: More loci, more assistance, more details
- Tech Newsletter #1: PIRCHE database update and new functions
- PIRCHE Kidney Transplantation – Integration in Today’s Routine
- Nils Lachmann’s Poster about PIRCHE® at DTG 2016 Receives Poster Award
- The PIRCHE® technology: Predicting HLA epitopes being indirectly recognized improves donor selection in various transplantation settings
- Cord Blood Symposium 2014: Poster Award for Kirsten Thus
- PIRCHE-II Is Related to Graft Failure after Kidney Transplantation (2018)
- Matching donor and recipient based on predicted indirectly recognizable human leucocyte antigen epitopes (2018)
- Donor-Recipient Matching Based on Predicted Indirectly Recognizable HLA Epitopes Independently Predicts the Incidence of De Novo Donor-Specific HLA Antibodies Following Renal Transplantation (2017)
- The Immunogenicity of HLA Class II Mismatches: The Predicted Presentation of Nonself Allo-HLA-Derived Peptide by the HLA-DR Phenotype of the Recipient Is Associated with the Formation of DSA (2017)
- Computational Approaches to Facilitate Epitope-Based HLA Matching in Solid Organ Transplantation (2017)
Get in Touch with PIRCHE!
Stuttgarter Platz 2